2. Epigenetics Metabolic Enzyme/Protease Immunology/Inflammation Apoptosis
  3. YTHDF FOXO MMP Pyroptosis Interleukin Related
  4. DC-Y13-27

DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (KD: 37.9 μM). DC-Y13-27 inhibits YTHDF2, restores FOXO3 and TIMP1 protein levels, and reduces MMP1/3/7/9 expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer.

For research use only. We do not sell to patients.

DC-Y13-27 Chemical Structure

DC-Y13-27 Chemical Structure

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 4 publication(s) in Google Scholar

DC-Y13-27 Related Antibodies

Top Publications Citing Use of Products

View All YTHDF Isoform Specific Products:

View All Isoforms
YTHDF1 YTHDF3 YTHDF2 YTHDC1 YTHDC2

View All FOXO Isoform Specific Products:

View All Isoforms
FOXO1 FOXO3

View All MMP Isoform Specific Products:

View All Isoforms
MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (KD: 37.9 μM). DC-Y13-27 inhibits YTHDF2, restores FOXO3 and TIMP1 protein levels, and reduces MMP1/3/7/9 expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer[1][2][3].

IC50 & Target[1][2][3]

YTHDF2

37.9 μM (Kd)

FOXO3

 

MMP-1

 

MMP3

 

MMP-7

 

MMP9

 

IL-1β

 

In Vitro

DC-Y13-27 binds to YTHDF2 with a binding constant (KD) of 37.9 μM[1].
DC-Y13-27 (20-40 μM; 6 h) co-treated with H2O2 reduces YTHDF2 expression, restores FOXO3 and TIMP1 protein levels, and decreases MMP1/3/7/9 expression in NP and AF cells[2].
DC-Y13-27 (24 h) inhibits cell proliferation, increases LDH release and IL-1β secretion, and induces pyroptosis in MDA-MB-231 and BT-549 cells[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DC-Y13-27 Related Antibodies
In Vivo

DC-Y13-27 (9 μg/mouse; i.v.; daily) combined with radiotherapy significantly inhibits tumor growth in C57BL/6J mice bearing MC38 colon cancer, B16 melanoma, or MC38 colon cancer[1].
DC-Y13-27 (5 mg/kg; s.c.; every 5 days; 12 weeks) alleviates intervertebral disc degeneration in aged mice and H2O2-induced IDD models[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 mice (8 weeks old initially) with aged or H2O2-induced IDD[2].
Dosage: 5 mg/kg
Administration: Subcutaneous injection near lumbar discs, every 5 days, for 12 weeks
Result: Reduced disc degeneration, increased FOXO3 and TIMP1 expression, and decreased MMP1/3/7/9 activity in IVD tissues.
Molecular Weight

270.31

Formula

C14H10N2O2S
Appearance

Solid

Color

Yellow to orange

SMILES

N#C/C(C(N)=O)=C\C1=CC=C(C2=CC(O)=CC=C2)S1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 116.67 mg/mL (431.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.6995 mL 18.4973 mL 36.9946 mL
5 mM 0.7399 mL 3.6995 mL 7.3989 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 10 mg/mL (36.99 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 10 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (100.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: 10 mg/mL (36.99 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 10 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (100.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.52%

SDS (251 KB)

COA (247 KB) HNMR (278 KB) RP-HPLC (247 KB) LCMS (101 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.6995 mL 18.4973 mL 36.9946 mL 92.4864 mL
5 mM 0.7399 mL 3.6995 mL 7.3989 mL 18.4973 mL
10 mM 0.3699 mL 1.8497 mL 3.6995 mL 9.2486 mL
15 mM 0.2466 mL 1.2332 mL 2.4663 mL 6.1658 mL
20 mM 0.1850 mL 0.9249 mL 1.8497 mL 4.6243 mL
25 mM 0.1480 mL 0.7399 mL 1.4798 mL 3.6995 mL
30 mM 0.1233 mL 0.6166 mL 1.2332 mL 3.0829 mL
40 mM 0.0925 mL 0.4624 mL 0.9249 mL 2.3122 mL
50 mM 0.0740 mL 0.3699 mL 0.7399 mL 1.8497 mL
60 mM 0.0617 mL 0.3083 mL 0.6166 mL 1.5414 mL
80 mM 0.0462 mL 0.2312 mL 0.4624 mL 1.1561 mL
100 mM 0.0370 mL 0.1850 mL 0.3699 mL 0.9249 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

DC-Y13-27 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

DC-Y13-27YTHDFFOXOMMPPyroptosisInterleukin Related(YTH) domain-containing family proteins (YTHDF)Forkhead box OMatrix metalloproteinasesILantitumorradiotherapyimmunotherapyMC38 colon cancerB16 melanomaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
DC-Y13-27
Cat. No.:
HY-154919
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.